About Contact Us Careers
Sign In

Rift Valley Fever (RVF) Treatment Market Size & Share by Transmission (Mosquito Vector, Cattle); Symptoms (Encephalitis, Hemorrhagic fever, Ocular Issues); Distribution Channel (Pharmacies, Hospital); Treatment (Medication, Supportive Care) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3640
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Rift Valley Fever Treatment Market size is anticipated to surpass USD 2 Billion by the end of 2036, expanding around 5% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of rift valley fever treatment was over USD 200 Million. The growth of the market can be attributed to the rising cases of rift valley fever. Mosquito-borne rift valley fever seems to grow in humans and animals owing to factors such as climate change that are creating ideal mosquito breeding grounds. Further, increased outbreaks accelerate the demand for supportive care and highlight the urgent need for specific treatments.  In people, the total RVF CFR was determined to be 27.5%. In people and animals, the overall pooled prevalence was 7.8% and 9.3%, respectively.  

As the threat of river valley fever expands, governments and research institutions are investing more money in developing new treatments and vaccines for the disease. This investment is likely to lead to the development of new and more effective treatments for river valley fever in the forecast period. Therefore, the development of new treatment options and medications for the river valley fever cure is further predicted to drive the growth of this market in the future times.

Rift Valley Fever Treatment Market
Get more information on this report: Request Free Sample PDF

Rift Valley Fever Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Surging Research and Development for Rift Valley Treatment – There is currently no specific antiviral treatment for rift valley fever. Patients are typically treated with supportive care such as fluids, pain, relievers, and blood transfusions. According to a report by the Centers for Disease Control and Prevention (CDC), there is no FDA-approved treatment for RVF, and mild symptoms are treated using over-the-counter medications. This lack of a specific treatment creates a significant unmet medical need and is driving investment in the development of new river valley fever treatment. However, symptoms of this deadly disease include fever, muscle pain, headache, loss of appetite, vomiting, and other flu-like symptoms at the early stage of infection. These can be treated using general fever medications, or the infected person develops immunity against the virus. However, in severe cases, symptoms can be serious, such as retinal lesions, meningoencephalitis, loss of memory, hallucinations, vertigo, and hemorrhagic fever. According to the data from the World Health Organization, only 0.5-2% of patients develop eye or ocular diseases, and less than 1% experience meningoencephalitis and hemorrhagic fever.
  • Increased Awareness About Rift Valley Fever- The awareness of rift valley fever among both the public and healthcare professionals. This is due to several factors, including media coverage of rift valley fever outbreaks and educational campaigns by public health organizations. This increased awareness is leading to increased demand for awareness is leading to increased demand for rift valley fever treatment and prevention measures.

Challenges

  • Inaccurate and Slow Diagnostics – Existing diagnostic tests for rift valley fever can be slow, expensive, and require specialized equipment, limiting access in resource-limited requins. Early detection and outbreak control are hampered by these bottlenecks. This is predicted to hamper the rift valley fever (RVF) treatment market growth in the upcoming period.
  • High Development Cost is another Substantial Factor Posing Limitation on the Market Expansion in the Future Times.
  • Limited Healthcare Resources Availability for the Treatment is Anticipated to Limit the Market Growth in the Forecast Period.

Rift Valley Fever (RVF) Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024 – 2036

CAGR

~5%

Base Year Market Size

~USD 200 Million

Forecast Year Market Size

~USD 2 Billion

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Rift Valley Fever Treatment Segmentation

Transmission (Mosquito Vector, Cattle)

In terms of transmission, the mosquito vector segment is anticipated to hold a prominent share of 70% in the global rift valley fever (RVF) treatment market during the forecast period on account of the higher proximity of infection transmission through mosquitoes, along with the lack of preventive methods in case of mosquito vector transmission. There is no requirement for direct contact with animals in case of transmission by mosquitoes, which makes it more dangerous and easier to spread. Such factors are estimated to boost the segment growth. Additionally, as the mosquitos are becoming the primary transmission route the rift valley fever prevention strategies increasingly target mosquito control. This further drive demand for insecticides, mosquito nets, and larvicides as a result driving the segment growth in this market.

Treatment (Medication, Supportive Care)

The medication segment in the rift valley fever treatment market is predicted to hold the largest revenue share of 60% by the end of 2036. Several promising antiviral drugs are in the development pipeline for rift valley fever. These target different stages of the viral replication cycle, offering the potential for more effective treatment. The successful development and commercialization of these drugs would significantly boost the medication segment of the market. Medication for fever and pain alleviation can be used to treat symptoms of the moderate type of RVF; however, individuals coming with severe symptoms are not yet treated with any specific or approved therapies.

Our in-depth analysis of the global market includes the following segments:

Transmission

  • Mosquito Vector
  • Cattle

Symptoms
  • Encephalitis
  •  Hemorrhagic fever
  •  Ocular Issues

Distribution Channel
  • Pharmacies
  • Hospital

Treatment
  • Medication
  • Supportive Care

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Rift Valley Fever Treatment Industry - Regional Synopsis

North American Market Forecasts

The rift valley fever (RVF) treatment market is predicted to hold the largest revenue share of 35% by the end of 2036. RVF is a mosquito borne viral disease that could be highly seen in Africa and North America. Anyhow, due to climate change and growing mosquito migration, there is a growing risk of rift valley fever outbreaks in North America. In 2020, there was an outbreak of rift valley fever in Texas that infected over 200 cattle. Furthermore, as the risk of RVF outbreaks grows in the North America region there is also a growing alertness of the disease among healthcare professionals and the general public. This is leading to an increased demand for information about rift valley fever and its treatment.

APAC Market Statistics

The rift valley fever treatment market in the Asia Pacific is predicted to grow significantly by the end of 2036. Rising disposable income and advancement in healthcare infrastructure in developing Asian countries such as India and China offer lucrative growth opportunities for the market in this region. Furthermore, growing spending on public health and biosecurity measures by governments further stimulates the market growth in the Asia Pacific region. Several pharmaceutical companies are actively involved in developing vaccines and antiviral drugs for RVF. Clinical trials Asia Pacific region hold promise for future market availability of effective rift valley treatments. Advancements in research and development are anticipated to contribute significantly to market expansion further.

Research Nester
Rift Valley Fever Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Rift Valley Fever Treatment Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.,
    • Siemens Healthcare GmbH
    • Pfizer Inc.
    • Eli Lilly and Company
    • Cipla Limited
    • Kemwell Biopharma Private Limited

In the News

  • Cipla Limited to collaborate with Kemwell Biopharma Private Limited  a leading global CDMO. The collaboration aims to make cost-effective biotherapeutics. To achieve this, a joint venture business will be established with the intention of breaking into the respiratory biosimilars market. In accordance with the terms of the agreement, the joint venture will make use of Cipla and Kemwell's complementary competencies for clinical development, end-to-end product development, regulatory filings, manufacturing, and biopharmaceutical product commercialization. The combination of Kemwell's biologics knowledge with Cipla's respiratory capability will hasten the release of these vital drugs.
  • Sandroz, a subsidiary of Novartis, declared the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics. Subject to the terms of the transaction, Sandoz would pay GSK USD 350 million at closing and up to a further milestone amount of USD 150 million. Subject to customary closing conditions, such as legal clearance, the transaction should be completed in the second half of 2021.

Author Credits:  Radhika Pawar


  • Report ID: 3640
  • Published Date: Jan 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of RVF and increasing awareness about the disease are some of the major factors anticipated to drive the growth of the rift valley fever treatment market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Eli Lilly and Company, and others.

The medication segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Rift Valley Fever Treatment Market Report Scope

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying